Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECC 2015 | Exploratory analysis of frontline therapies in REVEL: Phase 3 trial of ramucirumab in NSCLC

Giorgio Scagliotti • 26 Sep 2015
ECC 2015
Lung Cancer Docetaxel Ramucirumab

At the European Cancer Congress (ECC) 2015, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses the exploratory analysis of frontline therapies in REVEL, a randomized phase 3 trial of ramucirumab plus docetaxel versus docetaxel for the treatment of patients with stage IV non-small cell lung cancer (NSCLC) after disease progression on platinum-based therapy.

More from Giorgio Scagliotti

1:32
The IASLC: implementing personalized medicine in lung cancer
Giorgio Scagliotti • 3 Jul 2019
1:46
Predicting response to checkpoint inhibitors and overcoming resistance in lung cancers
Giorgio Scagliotti • 3 Jul 2019
1:53
Overcoming the challenges of precision medicine in lung cancer
Giorgio Scagliotti • 3 Jul 2019
3:23
More evidence needed to support checkpoint inhibitor use in late-stage cancer
Giorgio Scagliotti • 18 Jan 2019

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals